1. Home
  2. NTRA vs HOLX Comparison

NTRA vs HOLX Comparison

Compare NTRA & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • HOLX
  • Stock Information
  • Founded
  • NTRA 2003
  • HOLX 1985
  • Country
  • NTRA United States
  • HOLX United States
  • Employees
  • NTRA N/A
  • HOLX N/A
  • Industry
  • NTRA Medical Specialities
  • HOLX Medical Electronics
  • Sector
  • NTRA Health Care
  • HOLX Health Care
  • Exchange
  • NTRA Nasdaq
  • HOLX Nasdaq
  • Market Cap
  • NTRA 18.4B
  • HOLX 16.3B
  • IPO Year
  • NTRA 2015
  • HOLX 1990
  • Fundamental
  • Price
  • NTRA $148.08
  • HOLX $57.56
  • Analyst Decision
  • NTRA Strong Buy
  • HOLX Buy
  • Analyst Count
  • NTRA 17
  • HOLX 14
  • Target Price
  • NTRA $176.65
  • HOLX $84.17
  • AVG Volume (30 Days)
  • NTRA 1.6M
  • HOLX 3.7M
  • Earning Date
  • NTRA 05-08-2025
  • HOLX 05-01-2025
  • Dividend Yield
  • NTRA N/A
  • HOLX N/A
  • EPS Growth
  • NTRA N/A
  • HOLX 50.83
  • EPS
  • NTRA N/A
  • HOLX 3.16
  • Revenue
  • NTRA $1,696,911,000.00
  • HOLX $4,039,000,000.00
  • Revenue This Year
  • NTRA $15.33
  • HOLX $3.37
  • Revenue Next Year
  • NTRA $18.50
  • HOLX $5.40
  • P/E Ratio
  • NTRA N/A
  • HOLX $18.24
  • Revenue Growth
  • NTRA 56.75
  • HOLX 1.76
  • 52 Week Low
  • NTRA $83.13
  • HOLX $56.27
  • 52 Week High
  • NTRA $183.00
  • HOLX $84.67
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 50.83
  • HOLX 39.33
  • Support Level
  • NTRA $125.38
  • HOLX $56.27
  • Resistance Level
  • NTRA $152.66
  • HOLX $59.02
  • Average True Range (ATR)
  • NTRA 8.82
  • HOLX 2.18
  • MACD
  • NTRA 1.47
  • HOLX -0.19
  • Stochastic Oscillator
  • NTRA 82.19
  • HOLX 23.49

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About HOLX Hologic Inc.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Share on Social Networks: